日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden

在挪威和瑞典,伊诺妥珠单抗奥佐加米星与标准化疗方案相比,在治疗复发或难治性急性淋巴细胞白血病患者方面的成本效益分析

van Oostrum, I; Russell-Smith, T A; Jakobsson, M; Torup Østby, J; Heeg, B

Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment

常见问题,通用数据模型解决方案:卫生技术评估的证据生成

Kent, Seamus; Burn, Edward; Dawoud, Dalia; Jonsson, Pall; Østby, Jens Torup; Hughes, Nigel; Rijnbeek, Peter; Bouvy, Jacoline C

Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies

按需服用纳美芬治疗至少具有高饮酒风险水平的酒精依赖患者的疗效:两项随机对照6个月研究的亚组分析结果

van den Brink, Wim; Aubin, Henri-Jean; Bladström, Anna; Torup, Lars; Gual, Antoni; Mann, Karl

High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO)

与神经保护变体氨基甲酰促红细胞生成素 (CEPO) 相比,高剂量促红细胞生成素会改变啮齿动物的血小板反应性和出血时间

Agnete Kirkeby, Lars Torup, Louise Bochsen, Marianne Kjalke, Kristin Abel, Kim Theilgaard-Monch, Pär I Johansson, Søren E Bjørn, Jens Gerwien, Marcel Leist

Neuroprotection with or without erythropoiesis; sometimes less is more

神经保护作用,无论是否伴有红细胞生成;有时少即是多

Torup, L